KR30031 is a novel P-glycoprotein inhibitor with potential anticancer activity. KR30031 is a verapamil analogue with fewer cardiovascular effects. The ability of KR-30031 to reduce this efflux transport is equal to that of verapamil, a well-known P-glycoprotein inhibitor. The bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031. References: Werle M. Polymeric and low molecular mass efflux pump inhibitors for oral drug delivery. J Pharm Sci. 2008 Jan;97(1):60-70. Review. PubMed PMID: 17721883.

纯度：≥98%

CAS：205535-74-6